TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22705118

Group type: EXPERIMENTAL
Intervention: Biweekly combination therapy with gemcitabine (1000 mg/m²) and carboplatin (AUC 3) on days 1 and 15, every 4 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Gemcitabine monotherapy (1000 mg/m²) on days 1, 8, and 15, every 4 weeks
Number of subjects: 61
Study: 19948934

Group type: EXPERIMENTAL
Intervention: Intervention for prevention of depression
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Subgroup analysis (women and those with higher depression scores)
Number of subjects: 900
Study: 17369082

Group type: EXPERIMENTAL
Intervention: Valacyclovir 3g/day for 14 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20
Study: 15337871

Group type: EXPERIMENTAL
Intervention: 3-D computed tomography (MMS CT)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Axial computed tomography (Axial CT)
Number of subjects: 5
Study: 11349793

Group type: EXPERIMENTAL
Intervention: Local pulsated pressure treatment
Number of subjects: 35

Group type: COMPARATOR
Intervention: Gentamicin treatment
Number of subjects: 35
Study: 10443310

Group type: EXPERIMENTAL
Intervention: Anti-GPIIb/IIIa molecules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classical anti-aggregant drugs
Number of subjects: 0
Study: 7788006

Group type: EXPERIMENTAL
Intervention: Ceruloplasmin measurement in patients with NIDDM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 2085099

Group type: EXPERIMENTAL
Intervention: Breast-feeding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low protein formula (1.1 g/100 ml)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional protein formula (1.5 g/100 ml)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formula-fed groups (both low and conventional protein)
Number of subjects: 0
Study: 377971

Group type: EXPERIMENTAL
Intervention: Cefazolin, 1.0 gm administered intramuscularly and cephalothin, 2.0 gm administered intravenously at 6, 12, and 24 hours postoperatively
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 31541292

Group type: EXPERIMENTAL
Intervention: Adapted training modules (5 modules including postural stability, mobilisation of lower extremity joints, leg and trunk stabilisation, jumping and landing exercises, agility movements)
Number of subjects: 1130

Group type: COMPARATOR
Intervention: Standard programme (control group)
Number of subjects: 1130
Study: 29806081

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid, choline, and uridine‐5‐monophosphate supplementation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 62
Study: 27046159

Group type: EXPERIMENTAL
Intervention: Continued thienopyridine and aspirin after 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DAPT score ≥2 with continued thienopyridine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DAPT score <2 with continued thienopyridine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo and aspirin after 12 months
Number of subjects: 0
Study: 24398718

Group type: EXPERIMENTAL
Intervention: Core stabilization exercise with real-time feedback for 30 minutes per day for 6 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Core stabilization exercise (control group)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Core stabilization exercise with real-time feedback
Number of subjects: 19
Study: 23266537

Group type: EXPERIMENTAL
Intervention: u-Health services (telemonitoring and teleconsultation supplemented with home visits)
Number of subjects: 144
Study: 19789859

Group type: EXPERIMENTAL
Intervention: Lighter group (0.79 kg bat)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Heavier group (1.36 kg bat)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard group (1.08 kg bat)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Batters switching from 0.79 kg to 1.08 kg bat
Number of subjects: 30
Study: 18535192

Group type: EXPERIMENTAL
Intervention: Diabetic participants
Number of subjects: 2364
Study: 15990782

Group type: EXPERIMENTAL
Intervention: Cluster schedule (6-week)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Conventional schedule (12-week)
Number of subjects: 239
Study: 12923146

Group type: EXPERIMENTAL
Intervention: Laser zona drilling
Number of subjects: 128

Group type: COMPARATOR
Intervention: Acid Tyrode medium zona drilling
Number of subjects: 128
Study: 10337521

Group type: EXPERIMENTAL
Intervention: Continuous cervicothoracic epidural block (group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Stellate ganglion block (group B)
Number of subjects: 20
Study: 8642166

Group type: EXPERIMENTAL
Intervention: SADAS
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SADAS cognitive subscale
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SADAS noncognitive subscale
Number of subjects: 54

Group type: COMPARATOR
Intervention: ADAS
Number of subjects: 54
Study: 1736084

Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 302

Group type: COMPARATOR
Intervention: Simple recommendation
Number of subjects: 302
Study: 6863579

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg/day
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Amiloride-hydrochlorothiazide 5/50 mg/day
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Timolol 20 mg/day
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combination of timolol with hydrochlorothiazide
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combination of timolol with amiloride-hydrochlorothiazide
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 2889550

Group type: EXPERIMENTAL
Intervention: LN2974
Number of subjects: 10
Study: 28986164

Group type: EXPERIMENTAL
Intervention: Rosiglitazone treatment in T2D subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin treatment in T2D subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (T2D subjects before treatment)
Number of subjects: 0
Study: 26753767

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 0
Study: 24127651

Group type: EXPERIMENTAL
Intervention: ticagrelor
Number of subjects: 18421

Group type: COMPARATOR
Intervention: clopidogrel
Number of subjects: 18421
Study: 22356323

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 53202

Group type: COMPARATOR
Intervention: Fecal immunochemical testing (FIT)
Number of subjects: 53202
Study: 19629848

Group type: EXPERIMENTAL
Intervention: Prism adaptation (using 10 dioptre, 6 degree prisms)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham treatment (using plain glasses)
Number of subjects: 37
Study: 18517082

Group type: EXPERIMENTAL
Intervention: Sublingual allergen immunotherapy (SLIT)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Subcutaneous allergen immunotherapy (SCIT)
Number of subjects: 64
Study: 15855490

Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) in addition to current combination therapy for 4 weeks
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Didanosine (ddI)
Number of subjects: 111
Study: 14620660

Group type: EXPERIMENTAL
Intervention: Astropol polishing system
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Diagloss polishing system
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sof‐Lex polishing system
Number of subjects: 75
Study: 10918432

Group type: EXPERIMENTAL
Intervention: Oral granisetron (2 mg, 1 h before first daily fraction of radiation)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Oral ondansetron (8 mg, 1.5 h prior to each fraction of TBI)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Historical control group (no 5-HT3-receptor antagonist)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Oral granisetron
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Oral ondansetron
Number of subjects: 34

Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 34
Study: 8781794

Group type: EXPERIMENTAL
Intervention: One-Action Stent Insertion System (OASIS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional delivery system
Number of subjects: 20
Study: 1729516

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Avafortan
Number of subjects: 0
Study: 6743606

Group type: EXPERIMENTAL
Intervention: External cephalic version under tocolysis with intravenous ritodrine
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (no version attempted)
Number of subjects: 130
Study: 31568714

Group type: EXPERIMENTAL
Intervention: 20 mg of XEN1101
Number of subjects: 20
Study: 30047347

Group type: EXPERIMENTAL
Intervention: Increased consumption of sugars from sugar-sweetened beverages
Number of subjects: 22720

Group type: EXPERIMENTAL
Intervention: Consumption of sugars from fruit juices or dessert foods
Number of subjects: 22720
Study: 26723197

Group type: EXPERIMENTAL
Intervention: Foley catheter insertion with stylette
Number of subjects: 123

Group type: COMPARATOR
Intervention: Foley catheter insertion without stylette
Number of subjects: 123
Study: 24993981

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 2912

Group type: EXPERIMENTAL
Intervention: High-ceiling sulphonamide diuretics
Number of subjects: 2912

Group type: EXPERIMENTAL
Intervention: Medication acting via the renin-angiotensin system
Number of subjects: 2912

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2912

Group type: EXPERIMENTAL
Intervention: Non-selective β-blockers
Number of subjects: 2912
Study: 23081934

Group type: EXPERIMENTAL
Intervention: Pine nut allergens (albumin and vicilin)
Number of subjects: 10
Study: 20887614

Group type: EXPERIMENTAL
Intervention: Digoxin therapy
Number of subjects: 5010
Study: 17922448

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 15793108

Group type: COMPARATOR
Intervention: Bolus injection of 1 g every 8 h for 24 h
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 3-h infusion of 1 g every 8 h for 24 h
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 3-h infusion of 2 g every 8 h for 24 h
Number of subjects: 9
Study: 11902505

Group type: EXPERIMENTAL
Intervention: Palliative chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palliative care programmes
Number of subjects: 0
Study: 11789238

Group type: EXPERIMENTAL
Intervention: Shenmai injection (intravenous for 7 days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no Shenmai injection)
Number of subjects: 80
Study: 8815119

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 1504127

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional measures (mortality, morbidity, side effects)
Number of subjects: 0
Study: 6091245

Group type: EXPERIMENTAL
Intervention: Synchrodyn 1‐17, 100 micrograms i.m. a day for 15 consecutive days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Synchrodyn 1‐17
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cortisol circadian rhythm study
Number of subjects: 90
Study: 31528849

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannulae (HFNC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 100
Study: 30024544

Group type: EXPERIMENTAL
Intervention: Maekmoondong‐tang
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 27417705

Group type: EXPERIMENTAL
Intervention: Telmisartan 40mg orally 2 hours prior to surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 26029978

Group type: EXPERIMENTAL
Intervention: Spinach extract rich in thylakoids
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 23943316

Group type: EXPERIMENTAL
Intervention: Deferoxamine (DFO) at 62 mg/kg/day (up to a maximum daily dose of 6000 mg/day)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 324
Study: 21428978

Group type: EXPERIMENTAL
Intervention: Cortexolone 17α-propionate 1% cream
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 77

Group type: COMPARATOR
Intervention: Tretinoin 0·05% cream
Number of subjects: 77
Study: 18971897

Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 16490350

Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation (IPV) at 1.2 bar/250 cycles/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation (IPV) at 1.2 bar/350 cycles/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation (IPV) at 1.8 bar/350 cycles/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation (IPV) at 1.8 bar/250 cycles/min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pressure support ventilation (PSV)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Prolonged apnea trial in normal subjects
Number of subjects: 10
Study: 15017644

Group type: EXPERIMENTAL
Intervention: Collaborative treatment (gastroenterologist and psychologist working together)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Medical treatment directed at gastrointestinal function
Number of subjects: 41

Group type: COMPARATOR
Intervention: Psychological therapy
Number of subjects: 41
Study: 11051309

Group type: EXPERIMENTAL
Intervention: Expert system (PI) assistance during the experiment
Number of subjects: 12

Group type: COMPARATOR
Intervention: No expert system assistance (control)
Number of subjects: 12
Study: 9351621

Group type: EXPERIMENTAL
Intervention: Budesonide dry powder, 800 microg twice daily, delivered from a Turbuhaler
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 8463867

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (312 mumol of vitamin A as retinyl palmitate)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 3543579

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29607764

Group type: EXPERIMENTAL
Intervention: Postoperative rehabilitation programs
Number of subjects: 0
Study: 27929727

Group type: COMPARATOR
Intervention: Patching alone (Group A - control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Action video games with patching (Group B - study)
Number of subjects: 40
Study: 24449241

Group type: EXPERIMENTAL
Intervention: VMPT-VT (Bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance)
Number of subjects: 511

Group type: COMPARATOR
Intervention: VMP (Bortezomib-melphalan-prednisone)
Number of subjects: 511
Study: 21899797

Group type: EXPERIMENTAL
Intervention: Natto and viscous vegetables breakfast
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control meal (WR with non-viscous boiled soyabeans, potatoes, and broccoli)
Number of subjects: 11
Study: 21403595

Group type: EXPERIMENTAL
Intervention: Low-intensity whole body vibration (15 mins, 30 Hz, 0.3 g)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Higher intensity whole body vibration (2 × 3 mins, 12.5 Hz, 1 g)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no vibration)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Whole body vibration groups (both low and high intensity)
Number of subjects: 47
Study: 18602742

Group type: EXPERIMENTAL
Intervention: Adjuvant radiation treatment (ART) with 60 Gray (Gy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant radiation treatment (ART) with 60-64 Gy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant radiation treatment (ART)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no ART)
Number of subjects: 0
Study: 16645533

Group type: EXPERIMENTAL
Intervention: Nomegestrol acetate (NOMAc; 5 mg/day for 10 days x month for 12 months) plus calcium (1 g/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 36
Study: 12819322

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitor (ramipril)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dihydropyridine calcium channel blocker (amlodipine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blocker (metoprolol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower BP control goal (mean arterial pressure ≤ 92 mmHg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Usual BP control goal (mean arterial pressure 102 to 107 mmHg inclusive)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite outcome (reduction in GFR by 50%, end-stage renal disease, or death)
Number of subjects: 0
Study: 10992315

Group type: EXPERIMENTAL
Intervention: Cavalieri method of modern design stereology with MRI
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (five controls)
Number of subjects: 12
Study: 8795307

Group type: EXPERIMENTAL
Intervention: Systemic infusion via the brachial vein (Group S)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ipsipedal infusion via the dorsalis pedis vein (Group IP)
Number of subjects: 40
Study: 7936824

Group type: EXPERIMENTAL
Intervention: Fetuses with hemolytic disease (n = 15)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control fetuses (n = 26)
Number of subjects: 41
Study: 3217807

Group type: EXPERIMENTAL
Intervention: Vindesine (VDS) 4 mg/m2 IV weekly X 8, then every second week
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Lomustine (CCNU) 70 mg/m2 orally, cyclophosphamide (CTX) 1000 mg/m2 IV every 4 weeks, methotrexate (MTX) 20 mg/m2 orally days 15 and 18 of each course
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: CCNU + CTX + MTX + VDS (lower doses: CCNU 50 mg/m2, CTX 750 mg/m2, VDS 2 mg/m2)
Number of subjects: 259
Study: 29875101

Group type: EXPERIMENTAL
Intervention: 30 mg/day quizartinib
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 60 mg/day quizartinib
Number of subjects: 76
Study: 26150601

Group type: EXPERIMENTAL
Intervention: SB4 (50 mg subcutaneous weekly)
Number of subjects: 596

Group type: COMPARATOR
Intervention: ETN (50 mg subcutaneous weekly)
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: SB4
Number of subjects: 596

Group type: COMPARATOR
Intervention: ETN
Number of subjects: 596
Study: 26776356

Group type: EXPERIMENTAL
Intervention: Fibrin sealant patch (FSP; TachoSil)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Oxidized regenerated cellulose gauze (ORCG; Surgicel Original)
Number of subjects: 224
Study: 24106918

Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification - Interpretation (CBM-I) in Positive condition
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 89
Study: 21850615

Group type: EXPERIMENTAL
Intervention: Transradial approach (TRA) for primary PCI
Number of subjects: 108

Group type: COMPARATOR
Intervention: Transfemoral approach (TFA) with StarClose for primary PCI
Number of subjects: 108
Study: 19494176

Group type: EXPERIMENTAL
Intervention: Low-frequency electroacupuncture (n = 9)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Physical exercise (n = 5)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated control (n = 6)
Number of subjects: 20
Study: 17919618

Group type: COMPARATOR
Intervention: Tacrolimus monotherapy (MONO)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Tacrolimus combination therapy (COMBO)
Number of subjects: 58
Study: 15157791

Group type: EXPERIMENTAL
Intervention: 20 microg ethinylestradiol plus 150 microg desogestrel (20EE/DSG)
Number of subjects: 998

Group type: COMPARATOR
Intervention: 20 microg ethinylestradiol plus 100 microg levonorgestrel (20EE/LNG)
Number of subjects: 998
Study: 11536349

Group type: EXPERIMENTAL
Intervention: Therapist led workshop
Number of subjects: 45

Group type: COMPARATOR
Intervention: Booklet
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Workshop
Number of subjects: 45
Study: 9764968

Group type: EXPERIMENTAL
Intervention: L-NMMA (4 mg kg(‐1) h(‐1) continuous infusion with a front loaded bolus of 4 mg kg(‐1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (volume matched)
Number of subjects: 10
Study: 8556026

Group type: EXPERIMENTAL
Intervention: Behavior modification‐based (BM) weight reduction intervention
Number of subjects: 156

Group type: COMPARATOR
Intervention: Food addiction theory‐based (FD) weight reduction intervention
Number of subjects: 156
Study: 2238184

Group type: COMPARATOR
Intervention: 0 mg bendrofluazide
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: 1.25 mg bendrofluazide
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: 2.5 mg bendrofluazide
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: 5.0 mg bendrofluazide
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: 10 mg bendrofluazide
Number of subjects: 257
Study: 360764

Group type: EXPERIMENTAL
Intervention: Oral norephedrine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 30691153

Group type: EXPERIMENTAL
Intervention: Swimming training (12 weeks, 3 times per week, 60 min/session)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sedentary controls
Number of subjects: 0
Study: 28697099

Group type: EXPERIMENTAL
Intervention: Intensive nutrition counseling intervention by a registered dietitian throughout pregnancy and 6 months postpartum
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Intensive nutrition counseling intervention
Number of subjects: 300
Study: 26363720

Group type: EXPERIMENTAL
Intervention: Lurasidone 20-60 mg or 80-120 mg
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Lurasidone (continuation treatment)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo (switched to lurasidone)
Number of subjects: 416
Study: 24108252

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (0-80 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (doses >40 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 14